179 related articles for article (PubMed ID: 34553515)
1. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Gehlen H; Fisch J; Merle R; Trachsel DS
J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
[TBL] [Abstract][Full Text] [Related]
2. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
4. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
5. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
Rendle DI; Duz M; Beech J; Parkin T; Durham AE
J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
[TBL] [Abstract][Full Text] [Related]
6. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.
Tatum RC; McGowan CM; Ireland JL
Vet J; 2020 Dec; 266():105562. PubMed ID: 33323174
[TBL] [Abstract][Full Text] [Related]
8. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
McFarlane D; Banse H; Knych HK; Maxwell LK
J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
[TBL] [Abstract][Full Text] [Related]
11. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
Spelta CW; Axon JE
Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
[TBL] [Abstract][Full Text] [Related]
12. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
[TBL] [Abstract][Full Text] [Related]
13. Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction.
Hague N; Durham AE; Menzies-Gow NJ
Vet Rec; 2021 Jul; 189(1):e142. PubMed ID: 33759215
[TBL] [Abstract][Full Text] [Related]
14. Equine pituitary pars intermedia dysfunction.
McFarlane D
Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
[TBL] [Abstract][Full Text] [Related]
15. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction.
Pease AP; Schott HC; Howey EB; Patterson JS
J Vet Intern Med; 2011; 25(5):1144-51. PubMed ID: 21985144
[TBL] [Abstract][Full Text] [Related]
16. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy.
Banse HE; Whitehead AE; McFarlane D; Chelikani PK
Domest Anim Endocrinol; 2021 Jul; 76():106620. PubMed ID: 33740552
[TBL] [Abstract][Full Text] [Related]
17. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
Donaldson MT; LaMonte BH; Morresey P; Smith G; Beech J
J Vet Intern Med; 2002; 16(6):742-6. PubMed ID: 12465775
[TBL] [Abstract][Full Text] [Related]
18. The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses.
Durham AE
Vet J; 2022 Jul; 285():105831. PubMed ID: 35477010
[TBL] [Abstract][Full Text] [Related]
19. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
